Bristol Myers to Use Microsoft’s Imaging Network to Deploy FDA-Cleared AI for Earlier Lung Cancer Detection

Overview

• Bristol Myers Squibb signed an agreement to implement radiology AI via Microsoft’s Precision Imaging Network across U.S. care settings.
• The FDA-cleared algorithms analyze X-rays and CT scans to flag lung disease and hard-to-see nodules for radiologists.
• BMS says the workflow is designed to identify some patients at earlier stages and steer suspected NSCLC cases toward precision therapies.
• The plan emphasizes access for rural hospitals and community clinics, with tools to track lung nodule follow-up and reduce patient loss to care.
• The network is reported to be used by more than 80% of U.S. hospitals, positioning it for broad reach, and no real-world outcome data from this collaboration have been reported yet.